US Judge rejects Altria-Juul settlement proposal

Aug.30.2022
US Judge rejects Altria-Juul settlement proposal
A US judge rejected Altria Group's $117 million settlement over Juul Labs investment due to lacking sufficiency.

According to a report by Law360, a U.S. federal judge has denied preliminary approval of a $117 million settlement proposal between Altria Group and its shareholders regarding the company's investment in Juul Labs, stating that the proposed deal is "inadequate".


Photo: steheap. The lawsuit argues that in 2018, executives of Altria acted cautiously when they acquired a 35% stake in Juul for $12.8 billion.


According to shareholders, Altria executives are engaging in illegal and anti-competitive practices that have resulted in the loss of billions of dollars for the company. This is due to the increasing legal battles Juul is facing, as its products are suspected to pose a health risk and the company is alleged to have marketed to underage consumers. The plaintiffs argue that Altria was aware of this issue when investing, but chose to overlook it.


As Juul Labs faces increased litigation and regulatory scrutiny, the investment value of Altria has steadily declined.


The plaintiff argues for the approval of a settlement, stating that it is fair and reasonable to recover the cost and risk of further litigation. U.S. District Judge David J. Novak has not explained why he finds the settlement inadequate.


Statement:


This article is compiled from third-party information and is intended solely for industry communication and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness and accuracy of the article's content. The compilation of this article is only intended for industry communication and research.


Due to limitations in our translation capabilities, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related expressions or stances.


Copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
Philip Morris International (PMI) released its Q4 and full-year 2025 results on February 6, 2026. PMI reported full-year net revenues of $40,648 million ($40.6 billion), reported diluted EPS of $7.26 and adjusted diluted EPS of $7.54. PMI said smoke-free net revenues were $16.9 billion and represented 41.5% of total net revenues, with smoke-free products available in 106 markets and over 43 million estimated adult consumers.
Feb.06 by 2FIRSTS.ai
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24
Exclusive|Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
Exclusive|Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
China Tobacco Jiangsu IC appears to have developed a nicotine oral film product under the "Nanjing" brand, according to images circulating on Chinese social media. If confirmed, this could potentially mark China Tobacco's first oral nicotine product targeting the domestic market. The product's authenticity has not been officially verified, and no nicotine pouch products have been approved for sale in China.
Special Report
Feb.09
Russia’s Volgograd Police Seize Illicit Nicotine Products Worth Over US$42.9K+
Russia’s Volgograd Police Seize Illicit Nicotine Products Worth Over US$42.9K+
Police in Russia’s Volgograd region say they seized nicotine products lacking mandatory markings valued at more than RUB 3.3 million (about US$42,900+, using RUB 1 = US$0.013). A 43-year-old suspect allegedly stored and sold the products through two retail outlets in Volgograd’s Central and Dzerzhinsky districts. A criminal case has been opened under Article 171.1(6) of the Russian Criminal Code.
Jan.30 by 2FIRSTS.ai
Before the Boom:  Why Manufacturing Is Becoming the Deciding Factor in U.S. Nicotine Pouches — An Interview with Rena World
Before the Boom: Why Manufacturing Is Becoming the Deciding Factor in U.S. Nicotine Pouches — An Interview with Rena World
As the U.S. nicotine pouch market moves toward regulatory clarity and rapid growth, attention is shifting from demand to execution. In an interview with 2Firsts, U.S.-based manufacturer Rena explains why manufacturing capacity, quality systems, and compliance readiness are becoming decisive factors before the market fully takes off.
Jan.19
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire reported a sharp year-on-year revenue decline in Q2 FY2026 as it shifted away from lower-quality customers, while cutting operating expenses and narrowing its net loss. The company also highlighted improved collections, with net accounts receivable down nearly one-fifth since June 30, 2025, alongside ongoing manufacturing and technology initiatives.
Feb.09 by 2FIRSTS.ai